Dr. Brentjens on Managing Patients After CAR T-Cell Therapy

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses managing patients after treatment with chimeric antigen receptor (CAR) T-cell therapy.

There is an increasing amount of information on CAR T-cell therapy that will continue to shed light on the side effects of this type of treatment. If a center decides to use CAR T-cell therapy, Brentjens says that it is important to bring in specialists to deal with the associated side effects. This includes critical care specialists, neurologists, and infectious disease specialists.

This will optimize the ability to understand what is going on in patients after they receive CAR T-cell therapy, and minimize it, says Brentjens.